DAIICHI SANKYO CO. LTD (D4S.DU)
Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
28.35+0.18 (+0.64%)
As of 3:30PM CET. Market open.
| Previous close | 28.17 |
| Open | 28.34 |
| Bid | 28.35 x 0 |
| Ask | 29.04 x 0 |
| Day's range | 28.29 - 28.35 |
| 52-week range | 15.20 - 31.28 |
| Volume | 50 |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
- Zacks
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
- Motley Fool
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.
© 2021 Verizon Media. All rights reserved.
